DiamiR
DiamiR Biosciences is a molecular diagnostics company developing blood-based tests that detect brain-enriched microRNA biomarkers in plasma for early identification and monitoring of neurodegenerative disorders, serving pharmaceutical, biotech, and clinical research customers through its CLIA-certified laboratory.
- Company typePrivate
- Founded1998
- HeadquartersMonmouth Junction, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What DiamiR does
DiamiR Biosciences Corp. is a molecular diagnostics company developing blood-based tests for the early detection and monitoring of neurodegenerative and neurodevelopmental disorders, built on a proprietary platform that analyzes brain-enriched microRNA (miRNA) biomarkers detectable in blood plasma. The company exploits the discovery that certain microRNAs are enriched in specific brain regions (hippocampus, midbrain), cells (neurons), and synaptic compartments, and can cross the blood-brain barrier to be measured peripherally. Its lead product candidate, CogniMIR, targets early detection of mild cognitive impairment and Alzheimer's disease, while a broader Universal Screening Test (UST) program uses organ-enriched miRNA panels for early pathology detection across organ systems. A March 2026 publication in the journal Diagnostics also demonstrated feasibility of a plasma-based miRNA test for glioblastoma, signaling expansion into CNS oncology.
The company operates a CLIA-certified, CAP-accredited clinical laboratory in New Haven, CT, and maintains clinical laboratory permits in New York, Connecticut, Maryland, California, and Pennsylvania. It sells miRNA testing services to pharmaceutical and biotechnology companies, academic medical centers, and CROs for biomarker discovery, patient identification and recruitment, treatment response monitoring, and clinical trial support, with results delivered in 3-5 business days. Co-founders Kira Sheinerman, PhD, MBA and Samuil Umansky, MD, PhD, Dr Sci anchor the science; Umansky holds over 80 US and international patents. The IP portfolio is broad: issued and pending patents cover brain-enriched miRNA technology alongside transrenal nucleic acid methods. Pricing is quote-based with no publicly disclosed tiers.
In July 2025, DiamiR entered into a definitive all-stock merger agreement with Aptorum Group Limited (NASDAQ: APM), under which DiamiR will become a wholly-owned subsidiary and the combined company will be headquartered in Princeton, NJ. Aptorum filed a registered direct offering of up to $6 million to finance the merger and general operations. Strategic partnerships include Instant NanoBiosensors (APOE platform validation, February 2026), New York Blood Center (Healthy Aging program, NIH/NIA-funded), and Tri-State Rett Syndrome Center at Montefiore (Rett syndrome biomarker development). Revenue figures are not disclosed; cumulative grant funding totals approximately $7.5 million across 2017-2020 from SBIR, NIH/NIA, NINDS, and the Alzheimer's Drug Discovery Foundation.
DiamiR firmographics
Firmographics- Name
- DiamiR
- Legal name
- DiamiR Biosciences Corp.
- Website
- https://diamirbio.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- DiamiR Biosciences is a molecular diagnostics company developing blood-based tests that detect brain-enriched microRNA biomarkers in plasma for early identification and monitoring of neurodegenerative disorders, serving pharmaceutical, biotech, and clinical research customers through its CLIA-certified laboratory.
- Ownership category
- akta.pro rank
DiamiR industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
- akta.pro secondary industries
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
Keywords
Where DiamiR is headquartered
LocationHeadquarters
- HQ city
- Monmouth Junction
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
DiamiR business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- miRNA Testing Services: Laboratory testing services offered to pharmaceutical companies, researchers, and drug developers for biomarker discovery, patient identification, treatment monitoring, and clinical trial support. Services include sample collection, advanced miRNA expression analysis, and comprehensive reporting with 3-5 business day turnaround.
- Diagnostic Product Candidates: Development and potential commercialization of diagnostic products including CogniMIR for Alzheimer's disease detection and Universal Screening Test for organ health assessment.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
DiamiR product offering
Product offeringCore offering
DiamiR provides blood-based molecular diagnostic testing services and develops diagnostic product candidates based on brain-enriched microRNA biomarkers detectable in plasma. From its CLIA-certified, CAP-accredited clinical laboratory in New Haven, CT, the company offers miRNA testing services with 3-5 business day turnaround for pharmaceutical and biotechnology companies, researchers, and clinical trial operators. Lead diagnostic product candidates include CogniMIR for early detection of mild cognitive impairment and Alzheimer's disease and the Universal Screening Test for organ-level pathology detection.
Product overview
DiamiR offers a portfolio of blood-based molecular diagnostics focused on brain health, built on its proprietary platform of brain-enriched microRNA biomarkers detectable in plasma. The core offerings include CogniMIR for early detection of mild cognitive impairment and Alzheimer's disease, microRNA Testing Services for research and clinical study support, and the Universal Screening Test (UST) for organ-level pathology detection. The company operates a CLIA-certified, CAP-accredited clinical laboratory in New Haven, CT, and also provides APOE testing platform validation services in partnership with Instant NanoBiosensors. All products leverage non-invasive blood sampling to capture signatures of brain and synaptic health.
Differentiator
Problem solved
Functional benefit
Brands
- CogniMIR™: Lead product in development for early detection of mild cognitive impairment and Alzheimer's disease in the context of clinical studies.
Products and services
- CogniMIR Lead diagnostic product candidate using brain-enriched microRNA biomarkers in blood plasma for early detection of mild cognitive impairment and Alzheimer's disease, designed to support clinical study enrollment and disease monitoring for pharmaceutical and research customers.
- microRNA Testing Services Laboratory testing services analyzing microRNA expression patterns from blood, plasma, saliva, or tissue samples, delivered from DiamiR's CLIA-certified, CAP-accredited laboratory in New Haven, CT, for pharmaceutical companies, biotech firms, and research institutions needing biomarker discovery, patient identification, treatment monitoring, and precision diagnostics support.
- Universal Screening Test (UST) Blood-based universal screening test using organ-enriched microRNA panels to detect the presence of pathology in particular organ systems early, enabling follow-up with more specific diagnostic testing.
Quantifiable outcome
- Neurodegeneration in Alzheimer's disease begins 15-20 years prior to clinical manifestation, enabling presymptomatic diagnosis potential
- +1 more outcomes
Companies that use DiamiR
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
DiamiR technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
DiamiR partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core, flagship and minor.
- Instant NanoBiosensorscoreCollaboration to validate Instant NanoBiosensors' automated apolipoprotein E (APOE) testing platform for clinical use in DiamiR's CLIA-certified, CAP-accredited clinical laboratory. The validation aims to expand DiamiR's service offerings and strengthen confidence in the INB platform for Alzheimer's disease diagnostics.
- Aptorum Group LimitedflagshipDefinitive all-stock merger agreement where DiamiR will become a wholly-owned subsidiary of Aptorum Group. The merged company plans to operate under Nasdaq and will be headquartered in Princeton, New Jersey, with strategic focus on blood-based tests for brain health and other diseases.
- New York Blood CentercoreCollaboration on the Healthy Aging program, which is funded in part by a Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH). Program focuses on developing biomarkers of aging based on brain-enriched and inflammation-associated microRNAs in plasma.
- Tri-State Rett Syndrome Center at Montefiore Medical CenterminorClinical study collaboration to investigate the potential of brain-enriched microRNA as biomarkers of Rett syndrome (RTT). Initial work conducted in animal models suggests the approach for developing minimally invasive biomarkers is feasible.
- Academia, Medical Centers, Disease Foundations, and Industry CollaboratorsminorCollaborations with academia, medical centers, disease foundations and industry partners for development and commercialization of microRNA-based diagnostics for brain health and other diseases.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
DiamiR competitors and assessment
Company assessmentMarket position
Strengths3 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
DiamiR social profiles
Digital presenceDiamiR compliance and trust
Trust signalCompliance7 records
DiamiR financial estimates
Financial estimateRevenue estimate
Valuation estimate
DiamiR leadership team
Management profileNumber of profiles
Profiles6 records
DiamiR funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DiamiR M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DiamiR
What does DiamiR do?
DiamiR provides blood-based molecular diagnostic testing services and develops diagnostic product candidates based on brain-enriched microRNA biomarkers detectable in plasma. From its CLIA-certified, CAP-accredited clinical laboratory in New Haven, CT, the company offers miRNA testing services with 3-5 business day turnaround for pharmaceutical and biotechnology companies, researchers, and clinical trial operators. Lead diagnostic product candidates include CogniMIR for early detection of mild cognitive impairment and Alzheimer's disease and the Universal Screening Test for organ-level pathology detection.
Is DiamiR a public or private company?
DiamiR is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was DiamiR founded?
DiamiR was founded in 1998. It employs 1 to 10 people.
Where is DiamiR based?
DiamiR is headquartered in Monmouth Junction, United States, in the North America region.
How does DiamiR make money?
Two revenue lines are on record. miRNA Testing Services are the primary driver. The others are diagnostic Product Candidates.
Does DiamiR have an API?
No public API is recorded for DiamiR.
What industry is DiamiR in?
DiamiR's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 621511 and its SIC code is 8071.